Breaking News Headlines Today | Ground News

See every side of every news story

Pharmaceutical Business Review image

News from Pharmaceutical Business review

All of today’s top news stories from Pharmaceutical Business Review. Get the full analysis behind how media bias impacts breaking news.

We’ve discovered 60 headlines written by Pharmaceutical Business Review during the past 3 months.

Ground News rates Pharmaceutical Business Review’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical Business Review’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical Business Review

Where is Pharmaceutical Business Review located?Pharmaceutical Business Review's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical Business Review News

FDA Fast Tracks One-Time Intravitreal Gene Therapy for Geographic Atrophy

AMD · United States

FDA Fast Tracks One-Time Intravitreal Gene Therapy for Geographic Atrophy

100% Center coverage: 2 sources

The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to a press release from Sanofi.See the Story

Merck's SpringWorks Takeover Delivers a Drug Approval

Merck's SpringWorks Takeover Delivers a Drug Approval

100% Center coverage: 1 sources

Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.See the Story

Sun Pharma settles litigation with Incyte Corp

Pharma · United States

Sun Pharma settles litigation with Incyte Corp

100% Right coverage: 1 sources

Sun Pharma settles litigation with Incyte Corp See the Story

FDA Accepts sNDA for Sotyktu in PsA

Bristol Myers Squibb's deucravacitinib gains global regulatory acceptance for treating active psoriatic arthritis, promising a new oral treatment option.FDA · United States See the Story

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.Breast Cancer · United States See the Story

FDA grants orphan status for AlzeCure’s pain drug candidate

The company completed a positive Phase IIa trial of the candidate for chronic subjects with peripheral neuropathic pain. It is now preparing for further clinical development and has The post FDA grants orphan status for AlzeCure’s pain drug candidate appeared first on Pharmaceutical Business review.United States · United States See the Story

First Patient Dosed in Clinical Trial for Promising Dry AMD Therapy PST-611 – Patient Worthy

Coverage: 2 sources

A new milestone has been reached in the search for effective treatments for dry age-related macular degeneration (AMD), as the first patient has now been dosed in a clinical trial testing PST-611, a novel therapeutic candidate. This development, reported by Pharma Times, marks an important step forward in the effort to address a significant unmet […]AMD · Shanghai See the Story

Secarna, Vect-Horus partner to develop RNA-targeted therapeutics

This partnership will combine the OligoCreator technology of Secarna with Vect-Horus’ VECTrans system. The alliance uses Vect-Horus’ expertise in delivering compounds across biological barriers using its VECTrans platform. The post Secarna, Vect-Horus partner to develop RNA-targeted therapeutics appeared first on Pharmaceutical Business review.Read Article

Simcere Pharmaceutical seeks China approval for atopic dermatitis

This application aims to secure approval for treating adult and adolescent atopic dermatitis (AD). Under the partnership agreement, Connect Biopharma will receive up to approximately $110m in milestone The post Simcere Pharmaceutical seeks China approval for atopic dermatitis treatment appeared first on Pharmaceutical Business review.China · China Read Article

#Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals for Up to $25 Million,

'Rallybio Sells Interest in Rare Disease Program to Recursion Pharmaceuticals for Up to $25 Million' NEW HAVEN, Conn. '' Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company focused on the development of transformative therapies for patients with rare and devastating diseases, announced today that it has executed a definitive agreement to sell its interest in the REV102 program to joint venture partner Recursion Pharmaceut…Artificial Intelligence See the Story

Sagent and Qilu Announce Strategic Collaboration to Expand Access to Critical Injectables in U.S.

94% Center coverage: 18 sources

SCHAUMBURG, Ill., July 7, 2025 /PRNewswire/ -- Sagent Pharmaceuticals ("Sagent"), a leading provider of pharmaceuticals to the US market, and Qilu Pharmaceutical Co., Ltd. ("Qilu"), a leading vertically integrated pharmaceutical company based in China, today announced a strategic collaboration to…Pharma · Schaumburg See the Story

Breaking News Topics Related to Pharmaceutical Business Review